Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men
- 17 July 2007
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 74 (8), 1192-1201
- https://doi.org/10.1016/j.bcp.2007.07.015
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- Effect of Nicotine on Dynamic Function of Brain Catecholamine NeuronsPublished by Wiley ,2007
- α7 Nicotinic Receptor Gene Promoter Polymorphisms in Inbred Mice Affect Expression in a Cell Type-specific FashionPublished by Elsevier ,2007
- Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia PatientsAmerican Journal of Psychiatry, 2005
- Nicotine and Behavioral Markers of Risk for Schizophrenia A Double-Blind, Placebo-Controlled, Cross-Over StudyNeuropsychopharmacology, 2002
- The 5-HT 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonistBioorganic & Medicinal Chemistry Letters, 2001
- Protective Effect of GTS-21, a Novel Nicotinic Receptor Agonist, on Delayed Neuronal Death Induced by Ischemia in GerbilsThe Japanese Journal of Pharmacology, 1998
- Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literatureSchizophrenia Research, 1996
- Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: A pilot double blind transdermal nicotine positron emission tomography studyNeuropsychology Review, 1996
- Replication and Extension of P50 Findings in SchizophreniaClinical Electroencephalography, 1991
- Nicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivationActa Physiologica Scandinavica, 1990